Adverum Biotechnologies Inc
Change company Symbol lookup
Select an option...
ADVM Adverum Biotechnologies Inc
JRO Nuveen Floating Rate Income Opportunity Fund
SND Smart Sand Inc
EMR Emerson Electric Co
ZM Zoom Video Communications Inc
CYCN Cyclerion Therapeutics Inc
FRCGF Faircourt Gold Income Corp
BAC-O Bank of America Corp
AFT Apollo Senior Floating Rate Fund
LVO LiveOne Inc

Health Care : Biotechnology | Small Cap Growth
Company profile

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

Day's Change
0.01 (0.63%)
B/A Size
Day's High
Day's Low

Today's volume of 184,142 shares is on pace to be much lighter than ADVM's 10-day average volume of 1,004,150 shares.


PepsiCo Inc. Stock Underperforms Monday When Compared To Competitors

5:15 pm ET November 8, 2021 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of PepsiCo Inc. (PEP) slipped 2.15% to $162.43 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.09% to 4,701.70 and the Dow Jones Industrial Average rising 0.29% to 36,432.22. The stock's fall snapped a four-day winning streak. PepsiCo Inc. closed $4.00 below its 52-week high ($166.43), which the company reached on November 5th.

The stock underperformed when compared to some of its competitors Monday, as Nestle S.A. ADR (NESN.EB) fell 1.18% to $133.60, Coca-Cola Co. (KO) fell 0.90% to $56.33, and Unilever PLC ADR (ULVR.LN) fell 0.09% to $52.81. Trading volume (5.8 M) eclipsed its 50-day average volume of 3.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 8, 2021.

-MarketWatch Automation


(END) Dow Jones Newswires

November 08, 2021 17:15 ET (22:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.